Full-Time

Marketing Specialist

Posted on 11/23/2025

Altasciences

Altasciences

1,001-5,000 employees

Integrated CRO for early-phase drug development

No salary listed

Montreal, QC, Canada + 2 more

More locations: Laval, QC, Canada | Pointe-Claire, QC, Canada

Hybrid

90% remote; occasional on-site in Montreal/Dorval/Laval, QC.

Category
Growth & Marketing (1)
Required Skills
Drupal
MailChimp
Social Media
SEO
Salesforce
Google AdWords
Marketing
Video Editing
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Degree in Marketing, Advertising, or equivalent (Diploma of College Studies or Bachelor’s).
  • Three to five years in a marketing role.
  • Excellent copywriting and copy editing skills.
  • Highly organized, ability to work on multiple projects simultaneously with evolving priorities.
  • Solid understanding of social media (LinkedIn and Twitter).
  • Knowledge of Google Ads and Analytics, Salesforce, Mailchimp, and video editing tools.
  • Strong computer literacy (Outlook, PowerPoint, Excel, SharePoint, and Drupal).
  • Project management experience.
  • Strong attention to detail.
  • Knowledge of web analytics.
  • Bilingualism (French and English, written and spoken).
  • Ability to work autonomously and efficiently.
  • Conversion Rate Optimization or pharmaceutical industry experience will be considered an asset.
Responsibilities
  • Create marketing campaigns and tools to raise brand awareness and generate leads/sales: social media, e-blasts, digital advertisements, etc.
  • Developing and sourcing content for digital platforms.
  • Video creation and editing (series of Quick Chats, brand awareness, and others).
  • Assisting in search engine optimization optimization projects.
  • Identifying and engaging with vendors (especially to secure ad space, article publication, etc.).
  • Researching market trends.
  • Any other related tasks, such as formatting existing presentations, updating templates, proofreading, and short translations.

Altasciences provides an integrated CRO that handles the full early‑phase drug development path, from preclinical testing through clinical proof of concept and into manufacturing. Its approach combines discovery support, safety testing, clinical trial execution, and in‑house manufacturing to run programs under one roof. This contrasts with competitors that require pharma and biotech clients to source services from multiple vendors, adding complexity and risk; Altasciences streamlines the process by coordinating all steps. The company aims to help innovator drug programs move quickly and efficiently, delivering integrated data to de‑risk decisions and speed progression to later stages.

Company Size

1,001-5,000

Company Stage

Early VC

Total Funding

$6.7M

Headquarters

Laval, Canada

Founded

1976

Simplify Jobs

Simplify's Take

What believers are saying

  • Biotech/pharma consolidation demand for single-vendor early-phase development solutions increases.
  • 3D tissue technology adoption reduces animal testing costs and accelerates regulatory approval timelines.
  • Geographic footprint and participant database enable rapid enrollment for mid-size biopharma sponsors.

What critics are saying

  • Novo Holdings divesting Altasciences signals poor financial performance and operational cutbacks.
  • Charles River aggressive pricing on integrated packages captures 20% mid-size biopharma contracts.
  • AI-driven preclinical platforms from Insilico Medicine displace traditional animal safety pharmacology testing.

What makes Altasciences unique

  • Integrated CRO/CDMO spanning preclinical safety testing through Phase IV bioanalysis and manufacturing.
  • 9 North American facilities with 500,000+ participant database conducting 285+ trials annually.
  • VoxCell partnership integrates 3D tissue technology for human-relevant preclinical testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Employee Assistance & Telehealth Programs

Remote Work Options

Company News

GlobeNewswire
Mar 16th, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard...

Business Wire
Aug 20th, 2025
Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts

EcoVadis, the world's most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company's commitment to a sustainable future and a reduced environmental footprint.

Yahoo Finance
Jul 31st, 2025
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment.

Postmedia Network
Mar 28th, 2025
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category

For 14 years, Outsourced Pharma's CDMO Leadership Awards have recognized the top-performing contract development and manufacturing organizations based on comprehensive industry research, and feedback from sponsors.

BioSpace
May 29th, 2024
Altasciences Receives 2024 CRO Leadership Award for Capabilities

Altasciences receives 2024 CRO Leadership Award for Capabilities.

INACTIVE